Insmed to Present at the 35th Annual J.P. Morgan H

BRIDGEWATER, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the 35 ^th Annual J.P. Morgan Healthcare Conference on January 9-12, 2017 in San Francisco. Will Lewis, president and chief executive officer of Insmed, will deliver a corporate overview on Wednesday, January 11 at 7:30 AM PT.

Mr. Lewis’ presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com . The webcast will be archived for a period of 90 days following the live webcast.

About   Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral inhibitor of dipeptidyl peptidase I with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled prodrug formulation of treprostinil that may offer a differentiated product profile for rare pulmonary disorders. For more information, visit  www.insmed.com .

"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.

Investor Contact: Laura Perry Argot Partners 646.439.0410 laura@argotpartners.com